For our patients, the discovery of these actionable germline mutations led to recommendations for increased breast cancer surveillance with the addition of screening breast MRIs (for both ATM and CHEK2 mutation carriers) and more frequent colonoscopies for colon cancer surveillance (for CHEK2 mutation carriers only).42 Here, CHEK2 is linked to breast cancer.